Akebia Therapeutics, Inc. is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia markets Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved by the U.S. FDA in March 2024 for the treatment of anemia due to chronic kidney disease in adult dialysis patients, and Auryxia® (ferric citrate) for hyperphosphatemia and iron deficiency anemia. In its Q3 2026 Form 10-Q filing on November 5, 2026, Akebia disclosed an implemented 7% workforce reduction (~14 roles out of 194 staff) to streamline operational expenses and align capital with core commercial priorities, recording $1.3 million in quarterly restructuring charges while holding $159.3 million in cash and cash equivalents.
Ongoing U.S. commercial expansion and dialysis organization contracting for Vafseo (vadadustat)
Commercial nephrology biopharma Akebia Therapeutics disclosed in its Q3 2026 Form 10-Q filing on November 5, 2026, that it implemented a 7% workforce reduction (~14 positions eliminated from 194 staff) alongside earlier commercial reorganization efforts to improve operating efficiency and focus capital on the commercial execution of oral HIF-PH inhibitor Vafseo (vadadustat) and Auryxia (ferric citrate). The company recorded $1.3 million in Q3 restructuring charges ($3.3 million YTD) and closed September 2026 with $159.3 million in cash and cash equivalents against a quarterly net loss of $14.4 million.
Akebia Therapeutics disclosed in its Q3 2026 Form 10-Q an implemented 7% workforce reduction (~14 positions) and $1.3M in restructuring expenses to focus capital on Vafseo and Auryxia commercial execution.
President and Chief Executive Officer
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Commercial Officer
No active job listings. Check back later.